PEOPLE - SpectraScience makes appointment:
This article was originally published in Clinica
Executive Summary
SpectraScience (San Diego, California), manufacturer of minimally-invasive devices to diagnose cancerous tissue, has elected Stanley Pappelbaum to its board of directors. Dr Pappelbaum is the managing partner of California-based healthcare consultancy firm Pappelbaum, Turner & Associates.
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.